Allergy-Friendly Home DesignsVideo
Categories
- Allergy
- Alzheimer's Disease
- Arthritis
- Asthma
- Breast Cancer
- Cardio Health
- Cholesterol
- Cold and Flu
- Colon Cancer
- Diabetes
- Dieting
- Epilepsy
- Hair Loss
- Headache
- Heartburn
- HIV & AIDS
- Kidney Health
- Leukemia
- Lung Cancer
- Lymphoma
- Multiple Sclerosis
- Men's Health
- Mental Health
- Nutrition
- Osteoporosis
- Parkinson's Disease
- Prostate Health
- Skin Health
- Sleep Disorders
- Women's Health
- General
Immunotherapy Boosts Treatment of Kids' High-Risk Sarcomas
Posted on 08/04/2008, 09:00
By -- Robert Preidt
Patients with recurrent or metastatic disease had better-than-normal survival, study finds
MONDAY, Aug. 4 (HealthDay News) -- Immunotherapy shows promise in treating children with high-risk sarcomas, according to a U.S. National Institute of Health pilot study.
The study involved a new dendritic vaccine as well as a standard flu vaccine to potentially strengthen the immune system following chemotherapy.
While the dendritic vaccine didn't perform as well as hoped, children did respond well to the standard flu vaccine. This suggests that boosting immune function in children with sarcoma may be an effective approach. The dendritic vaccine included peptides derived from each patient's individual cancer in a way designed to alert the system to the unique genetic alteration on the cancer cells.
The study of 52 patients with recurrent and/or metastatic Ewing's sarcoma or alveolar rhabdomyosarcoma also found that those who received immunotherapy had better-than-normal survival. Patients who received immunotherapy had a 43 percent five-year overall survival, compared to 31 percent for those who didn't receive immunotherapy.
Overall, outcomes for these tumors have improved over the past 40 years, but there hasn't been substantial improvement for patients with recurrent or metastatic disease, noted the study's senior investigator, Dr. Crystal Mackall, of the National Cancer Institute's Pediatric Oncology Branch.
"This study shows that immunotherapy is safe and well-tolerated, and could ultimately be beneficial for this high risk population," she said in an American Association for Cancer Research news release. "We now know that the immune system of patients recovering from chemotherapy is malleable, so we just need to find the best immunological approach to exploit this window of opportunity."
The study was published in the Aug. 1 issue of the journal Clinical Cancer Research.
More information
The Sarcoma Foundation of America has more about sarcoma.
SOURCE: American Association for Cancer Research, news release, Aug. 1, 2008
Copyright © 2008 ScoutNews, LLC. All rights reserved.
BigHealthTree.com Disclaimer
Bighealthtree.com Does Not Provide Medical Advice. This site, including the above information, is for informational purposes only and is not a substitute for professional medical or health advice. Always seek the advice of your physician or a qualified health or medical professional before starting any new treatment, changing existing treatment, or altering your current exercise and/or diet program. If you think you are having a medical emergency, call 911 (or the emergency services in your area) or your doctor immediately.
Asthma Seasons
Beta Blockers Risk
Tai Chi Asthma
Ginko Study
Kids Apnea
Legionnaire Nurse
PTSD Dogs
Stress Age
AIDS Clots
Diabetes Cancer Drug
Hand Rejuvenation
PMS Linked to Smoking
HPV Cancer Data
Exercise Stroke

Comments (0):
Be the first to comment on this article.
Post a comment